|1.||Duvic, Madeleine: 14 articles (08/2013 - 01/2002)|
|2.||Dang, Nam H: 7 articles (01/2015 - 04/2004)|
|3.||Foss, Francine: 7 articles (07/2011 - 12/2003)|
|4.||Prince, H Miles: 5 articles (08/2013 - 05/2004)|
|5.||Foss, Francine M: 5 articles (07/2013 - 03/2002)|
|6.||Kreitman, Robert J: 5 articles (01/2009 - 02/2003)|
|7.||Walker, Pamela L: 5 articles (08/2007 - 04/2004)|
|8.||Goy, Andre: 4 articles (07/2013 - 10/2004)|
|9.||Olsen, Elise A: 4 articles (03/2013 - 03/2002)|
|10.||Talpur, Rakhshandra: 4 articles (06/2012 - 01/2002)|
11/01/2000 - "DAB(389)IL-2 has given complete or partial remission in 30% of highly refractory patients with extensive plaques and disfiguring tumors. "
04/15/2012 - "However, denileukin diftitox (DT)-mediated Treg depletion improved tumor-specific immunity and was clinically effective only in young mice. "
08/01/2012 - "These finding should be considered when denileukin diftitox is used for the treatment of patients suffering from tumors and/or autoimmune disorders."
08/01/2012 - "Meanwhile, denileukin diftitox is also used as an adjuvant in other tumor therapies and neoplastic disorders. "
03/01/2012 - "While the therapeutic vaccine primed the tumor-reactive CD8+ CTLs and CD4+ effector T lymphocytes (Teffs) compartment, inducing activation, tumor infiltration, and tumor rejection or delay in tumor growth, treatment with Ontak 1 day prior to vaccination resulted in enhanced CD4+ and CD8+ T-cell-mediated vaccine-specific immune responses in the periphery. "
|2.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/01/2013 - "In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. "
03/01/2013 - "This open-label phase III trial, a companion to an earlier placebo-controlled trial, evaluated safety and efficacy of denileukin diftitox (DD) in patients with cutaneous T-cell lymphoma (CTCL) who relapsed after responding to DD primary treatment in the earlier trial. "
08/01/2013 - "Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies."
04/10/2010 - "Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma."
01/15/2001 - "Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma."
|3.||Non-Hodgkin Lymphoma (Lymphosarcoma)
12/01/2007 - "Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497."
02/01/2007 - "Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma."
10/15/2004 - "Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma."
04/01/2004 - "Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma."
02/01/2007 - "This phase II study evaluated the safety and efficacy of denileukin diftitox, an interleukin-2-diphtheria toxin fusion protein, in relapsed/refractory T-cell non-Hodgkin lymphoma (T-NHL), excluding cutaneous T-cell lymphoma. "
|4.||Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
06/01/2012 - "Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas."
06/01/2012 - "This is a prospective, single center, pilot study of denileukin diftitox (Dd) in patients with persistent or recurrent cutaneous peripheral T-cell lymphomas and mycosis fungoides (MF) variants, excluding Sézary syndrome (SS). "
01/01/2015 - "Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission."
07/01/2008 - "De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission."
01/01/2002 - "Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)."
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
12/01/2001 - "We examined the safety and efficacy of denileukin diftitox in patients with severe plaque-type psoriasis. "
12/01/2001 - "However, this dosing regimen was better tolerated than the dosing regimen used in the last study with denileukin diftitox in psoriasis patients."
12/01/2001 - "The potential antipsoriatic activity of denileukin diftitox demonstrated in this study was comparable to that observed in other psoriasis studies with this agent. "
12/01/2001 - "A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis."
11/01/2000 - "DAB(389)IL-2 has been examined in clinical trials of psoriasis and rheumatoid arthritis and has shown promising results. "
|1.||denileukin diftitox (Ontak)
|8.||Interleukin-2 Receptors (IL 2 Receptor)
|2.||Drug Therapy (Chemotherapy)
|3.||Hematopoietic Stem Cell Transplantation